Stuart Travers
Oprichter bij Sentinel Oncology Ltd.
Profiel
Stuart Travers is the founder of Sentinel Oncology Ltd.
where he holds the title of Chief Operating Officer & Director since 2005.
He previously worked as a Principal at Millennium Pharmaceuticals, Inc., Cambridge Discovery Chemistry, Paradigm Therapeutics Ltd., and Glaxo Wellcome, Inc.
Actieve functies van Stuart Travers
| Bedrijven | Functie | Begin |
|---|---|---|
Sentinel Oncology Ltd.
 Sentinel Oncology Ltd. BiotechnologyHealth Technology Sentinel Oncology Ltd. operates as a molecule drug discovery company. The firm develops and commercializes new therapeutics to treat cancer where there is an unmet medical need. The company was founded by Stuart Travers, Robert G. Boyle, Ashok Venkitaraman and Gavin Simpson in 2005 and is headquartered in Cambridge, the United Kingdom. | Oprichter | 01-01-2005 |
Eerdere bekende functies van Stuart Travers
| Bedrijven | Functie | Einde |
|---|---|---|
| Glaxo Wellcome, Inc. | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Cambridge Discovery Chemistry
 Cambridge Discovery Chemistry Miscellaneous Commercial ServicesCommercial Services Part of Signature BioScience, Inc., Cambridge Discovery Chemistry provides chemistry research services. Cambridge Discovery Chemistry was acquired by Signature BioScience, Inc. from Millennium Pharmaceuticals, Inc. on July 16, 2001. | Corporate Officer/Principal | - |
Paradigm Therapeutics Ltd.
 Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Sentinel Oncology Ltd.
Sentinel Oncology Ltd. BiotechnologyHealth Technology Sentinel Oncology Ltd. operates as a molecule drug discovery company. The firm develops and commercializes new therapeutics to treat cancer where there is an unmet medical need. The company was founded by Stuart Travers, Robert G. Boyle, Ashok Venkitaraman and Gavin Simpson in 2005 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Cambridge Discovery Chemistry
Cambridge Discovery Chemistry Miscellaneous Commercial ServicesCommercial Services Part of Signature BioScience, Inc., Cambridge Discovery Chemistry provides chemistry research services. Cambridge Discovery Chemistry was acquired by Signature BioScience, Inc. from Millennium Pharmaceuticals, Inc. on July 16, 2001. | Commercial Services |
| Glaxo Wellcome, Inc. | Health Technology |
